ArticleCell biomaterials2025
The mucosal protein corona in local nanoparticle drug delivery.
Article in Cell biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineering Oral Nanoparticles: Navigating Biological Barriers in the Gastrointestinal Tract.Pharmaceutical research · 2026Review
- Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026Review
- Preparation and biomedical applications of single-metal atom catalysts.Nature protocols · 2026Review
- Decoy Nanoparticles and Protein Corona Modulation: A Novel Frontier in Sepsis Treatment.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
For therapeutic delivery to the gastrointestinal, ocular, respiratory, and vaginal surfaces to be effective, formulations must be engineered to overcome the protective mucus barrier. To accomplish this, nanoparticle-based formulations designed to avoid entrapment in mucus have proven to be an ideal platform to improve the retention and delivery of therapeutic cargos to mucosal tissues. However, most of the past work in this area has not considered how proteins and lipids present in the mucus matrix impact the transport, distribution, and uptake of locally delivered nanoparticles. Despite decades of research examining the protein corona formed on systemically administered nanoparticles, very little is known regarding the protein corona formation and biological identity of mucus-exposed nanomaterials. This perspective highlights recent findings as well as outstanding questions surrounding the mucosal protein corona of locally delivered nanoparticle formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.